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Abstract  
 
Activation of myofibroblast rich stroma is a rate-limiting step essential for cancer progression. The 
responsible factors are not fully understood, but TGF1 is probably critical. A proportion of TGF1 is 
associated with extracellular nano-vesicles termed exosomes, secreted by carcinoma cells, and the 
relative importance of soluble and vesicular TGF in stromal activation is presented. Prostate cancer 
exosomes triggered TGF1 dependent fibroblast differentiation, to a distinctive myofibroblast 
phenotype resembling stromal cells isolated from cancerous prostate tissue; supporting 
angiogenesis in vitro and accelerating tumour growth in vivo. Myofibroblasts generated using 
soluble-TGF1 were not pro-angiogenic or tumour-promoting. Cleaving heparan sulphate side 
chains from the exosome surface had no impact on TGF levels yet attenuated SMAD-dependent 
signalling and myofibroblastic differentiation. Eliminating exosomes from the cancer cell secretome, 
targeting Rab27a, abolished differentiation and lead to failure in stroma-assisted tumour growth in 
vivo. Exosomal-TGF1 is therefore required for the formation of tumour promoting stroma. 
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Introduction  
In prostate, and other, carcinomas the interstitial stroma is often abnormally rich in 
myofibroblastic cells (1, 2) capable of supporting tumour growth, partly through encouraging 
angiogenesis (3-5). Stromal gene signatures can predict treatment response in breast cancer (6), and 
more generally, high stroma to tumour ratios appears indicative of poor prognoses (1, 7, 8). 
Therapeutics targeting stromal activation may therefore be attractive, but there remain many 
unanswered questions about how cancer cells communicate with and co-opt stromal cells into 
participating in the pathological process. 
An assortment of epigenetic regulators, matrix components, cytokines and other factors are 
implicated in myofibroblast-induction, and phenotypic regulation. TGF, however, is of critical 
importance in generating tumour-reactive stroma (2, 9). Stromal differentiation requires engagement 
of the TGF type I (ALK5) and type II receptors, driving SMAD dependent and independent 
intracellular signalling events. This modulates transcription of a host of target genes (9, 10) including 
alpha-smooth muscle actin (SMA) which, together with cell contractility, is the principal 
myofibroblast marker (11). 
Although TGF is secreted at high levels as soluble homodimers by carcinomas; a proportion is 
also secreted in association with nanometre-sized extracellular vesicles, termed exosomes, which can 
trigger both canonical and non-canonical TGF signalling pathways (12, 13). This phenomenon, 
however, is not yet widely appreciated. Exosomes are typically less than 150nm in diameter, 
originating from within multivesicular endosomes (14). They harbour a complex molecular repertoire 
of lipids (15), proteins (16) and RNA (17), and can modulate cellular responses by a variety of 
molecular mechanisms.  Cancer exosomes exhibit well documented immune regulatory functions 
(18), many of which have been attributed to exosomal-TGF1 (12, 19-21). Exosomes influence other 
aspects of cancer biology, including metastasis (22, 23) and angiogenesis (24-27), yet few studies 
have investigated the function(s) of exosomes in the context of tumour-stroma activation.  
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We recently showed that cancer exosomes can trigger fibroblast to myofibroblast differentiation. 
This was dependant on exosomal-TGF  and the heparan sulphate proteoglycan, Betaglycan (12). 
The relative potency, however, of soluble TGF compared to its exosome-associated form is 
unknown. Similarly, the physiological relevance of exosomal-TGF in modulating cancer stroma 
has not been well explored. In this report, we hypothesized that cancer-derived exosomes are a 
component of tumour to stromal cell communication required for generating a tumour-supporting 
stromal phenotype.    
We present novel data demonstrating the necessity for cancer exosomes to drive stromal 
differentiation to a disease-associated phenotype. This phenotype is distinct from that generated by 
soluble TGF, as it exhibits pro-angiogenic and tumour growth-promoting characteristics. We show 
heparan sulphate side-chains, at the exosome surface, control the qualitative nature of exosomal-
TGF delivery, as loss of such chains attenuates SMAD-dependent TGF signalling and abrogates 
stromal differentiation without impacting the TGF dose presented. Furthermore, exosome-
deficient cancer cells fail to gain stroma-mediated growth advantage in vivo. Together these data 
highlight unique functional properties of exosomal-TGF, and implicate exosomes as key 
modulators of stroma in prostatic cancer, and likely other scenarios. 
 
Results 
 
Cancer exosomes trigger distinctive fibroblast differentiation.  
As an initial model, we treated lung fibroblasts with Du145 exosomes, characterised in Figure S1 
and shown previously as TGF-positive (12). Exosomes or dose-matched soluble TGF (sTGF1) 
significantly elevated expression of the principal myofibroblast marker, SMA, plus other 
characteristic features, including EDA-Fibronectin. A myofibroblast-specific antibody, PR2D3, (28) 
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demonstrated positive expression following exosome or sTGF treatment. Inhibition of TGF 
signalling, using an ALK5 inhibitor (SB431542), attenuated this exosome effect. In contrast, the 
mesenchymal marker, Vimentin, was expressed constitutively, and was not altered by treatment. The 
data reveal a myofibroblast phenotype that was similar following exosome or sTGF treatment 
(Fig1A), consistent with our previous report (12). 
We next explored possible differences in secreted factors following exosome or sTGF treatment. 
Using a low density protein array, we examined expression of 55 proteins of known associations with 
angiogenesis (Fig1B, C), revealing several differences. For example uPA, and HGF were 
preferentially elevated by exosomes (Fig1C, dark bars), whilst PDGF-AA and IGFBP-3 were better 
elevated by sTGF (Fig1C). We confirmed some of these results by ELISA, comparing exosomes 
with sTGF at several matched doses; demonstrating superior exosome-mediated elevation of uPA, 
HGF, FGF2, and VEGF-A (Fig1D). Confirmatory ELISA of purified exosomes, in the absence of 
fibroblasts, showed low levels of some of these factors were detectable (specifically 556pg/ml uPA, 
0pg/ml HGF, 15.2pg/ml FGF2, 581pg/ml VEGF, when adding exosomes at an equivalent TGF 
dose of 1.5ng/ml). These were too low to account for the levels measured in fibroblast-culture 
medium, pointing to the onset of de novo production of these factors. Real-time PCR revealed 
elevated mRNA for these factors following exosome treatment, with relative expression above that of 
sTGF stimulation. Exosomally-induced mRNA was inhibited in the presence of the ALK5 
inhibitor SB431542 (Fig1E).  Protein array data comparing exosome treatment vs exosome & 
SB431542  also revealed most of the exosome-mediated alterations were TGF sensitive, with 
HGF, FGF2 and VEGF inhibited by 50% or greater by SB431542 (Fig1F). Exosomes trigger TGF-
dependent differentiation of fibroblasts into distinctive myofibroblasts compared to the classical 
stimulus of soluble TGF. 

Exosome-induced myofibroblasts modulate endothelial cells.  
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Many of the elevated growth factors are pro-angiogenic, so we performed a series of experiments 
to evaluate the myofibroblast influence on various aspects of endothelial cell biology in vitro.  
Human umbilical vein endothelial cells (HUVEC) were stimulated with fibroblast conditioned media, 
collected 72h after treatment with exosomes or sTGF. After 24h, HUVEC highly expressed CD31 
and CD105, and this was unaltered by treatment. There was some increase in ICAM-1 and VCAM-1 
expression (Fig2A), by exosome-treated fibroblast culture medium, but this was not inhibited by 
SB431542, and therefore a TGF-independent effect. Examining proliferation revealed strong 
stimulation by exosome-treated fibroblast culture medium. This was, however, inhibited by 
SB431542. In contrast, culture medium from sTGF-treated fibroblasts had a much weaker influence 
(Fig2B). At 72h, there was no difference in the proportion of viable HUVEC in the differentially 
treated fibroblast culture medium (Fig2C), suggesting little difference in terms of HUVEC survival. 
HUVEC monolayers were subjected to a scratch (Fig2D), prior to addition of fibroblast culture 
medium. The rate of scratch closure, monitored microscopically, was accelerated by culture medium 
from exosome-treated fibroblasts. This was partially attenuated by SB431542. Myofibroblasts, 
generated by sTGF had no impact on endothelial migration rate, matching the rate of spontaneous 
closure.  
In a vessel formation assay (29), HUVEC co-cultured with untreated monolayers of fibroblasts 
had little effect, and supported only occasional CD31-positive cell clusters (Fig2E). Exosome-treated 
fibroblasts, however, supported formation of elaborate networks of vessel-like structures, forming 
multiple cross-bridges with neighbouring vessels. In contrast, fibroblasts treated with exosomes and 
SB431542 supported structures that were narrower with less branching, whilst stimulation with 
sTGF exhibited sparse CD31-positive structures akin to untreated fibroblasts. In summary, 
exosome-generated myofibroblasts, but not those generated using sTGF, can positively influence 
multiple properties of endothelial cell function, and are pro-angiogenic in nature. 
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Exosomal heparan sulphate chains are required to drive such distinctive myofibroblast 
differentiation.  
We next investigated how exosomes might mediate these TGF-dependent yet distinctive effects on 
fibroblasts. Our previous study demonstrated a role for exosomally expressed Betaglycan in binding 
TGF1, so we hypothesised that the heparan sulphate side chains of this transmembrane 
proteoglycan were involved in exosome-fibroblast interactions. We treated exosomes with 
heparinase-III, cleaving at the 1-4 linkages between hexosamine and glucuronic acid residues in 
heparan sulphate, liberating mainly disaccharides from proteoglycan protein backbones. As evidence 
of successful digestion, western blotting using an anti-HS antibody, recognising the remaining 
glycan stubs attached to the protein backbone (30), reveals distinct protein bands corresponding to 
various exosomally expressed proteoglycan protein cores (Fig3A). Without enzyme digestion, or 
treatment with heat inactivated enzyme, no staining was apparent yet bands of comparable intensity 
were seen when staining for GAPDH or TSG101.   
 
We next determined the impact of such digestion on exosomal-TGF, revealing enzymatic 
treatment, followed by two ultracentrifugation washes, made no difference whatsoever in the level of 
exosomal-TGF measured by ELISA (Fig3B), confirming direct association of TGF with the 
protein backbone of Betaglycan. The ability of exosomes to drive SMAD3-dependent TGF 
signalling was, however, attenuated following heparinase-III digestion (Fig3C), demonstrating that 
whilst HS-side chains play no role in tethering TGF to the exosome surface they are vital for 
signalling-competent delivery of TGF to the target cell. Heparinase-III digested exosomes are, 
therefore, unable to induce fibroblast SMA expression (Fig3D). Furthermore, fibroblasts treated 
with enzyme digested exosomes failed to support angiogenesis, demonstrated by total inhibition of 
CD31-positive structures in the vessel formation assay (Fig3D, E). An additional control involved 
ultracentrifugation washing (x2) of  heparinase-III only, prior to addition of any pelleted material to 
exosomes followed by adding to fibroblasts. This revealed no enzyme-related effects, consistent with 
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having effectively removed trace enzyme by this washing approach (Fig3D, E). We also explored 
levels of growth factors present in fibroblast CM following such treatments, showing enzyme 
treatment of exosomes significantly diminished HGF and VEGF secretion by fibroblasts, whilst 
deactivated enzyme had a weaker (VEGF) or negligible (HGF) effect (Fig3F). These experiments 
demonstrate heparan sulphate side chains on the surface of exosomes are required for functional 
TGF1 delivery to fibroblasts, as without these side chains, differentiation into pro-angiogenic 
fibroblasts doesn’t occur.  
 
Exosomes activate normal prostate stroma to become disease-like, in phenotype and 
function.  
Fresh tissue was obtained from prostate cancer patients undergoing radical retropubic 
prostatectomy. Tumour-associated cores were obtained from patients with pathology results 
indicating disease in only one side of the prostate (Fig4A, right). Additional cores from regions with 
no sign of macroscopic disease were also taken from the same patient (Fig 4A, left). The tissue 
sections were examined by an independent histopathologist, and for the example shown, classified as 
cancerous (Gleason score 7) or normal, respectively. 
Stromal cell cultures (Fig4B) established from these specimens were positive for Vimentin, and 
negative for Desmin, indicating a fibroblastic rather than a smooth-muscle phenotype.  Cells from the 
normal stroma were SMA negative, but could be stimulated to differentiate, becoming strongly 
positive for SMA following treatment with exosomes or sTGF1 (Fig4B, C).  In contrast, cells 
isolated from diseased tissue were constitutively but heterogeneously positive for SMA, exhibiting 
a myofibroblastic-like phenotype without requiring stimulation (Fig4B, C). 
We examined soluble factors secreted by stromal cultures, both constitutively and following 
stimulation with exosomes or sTGF. Exosome treatment stimulated elevated VEGF-A, uPA, HGF 
and a modest rise in FGF2 by normal stroma (Fig4D), whilst sTGF gave weaker elevation in 
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VEGF-A and uPA with HGF and FGF2 remaining unchanged. These are similar to the findings using 
the lung fibroblasts. Diseased stroma constitutively produced high levels of VEGF-A, uPA, HGF 
and, to some degree, FGF2 (Fig4D). Activation of normal stromal cells by exosomes, therefore, 
generated a myofibroblast cytoskeletal and secretory phenotype resembling those of diseased tissue. 
The angiogenic function of primary stromal cells was explored using the vessel formation assay. 
The data show untreated normal stroma was poor at supporting formation of vessels. Activation with 
sTGF failed to enhance this, as staining for CD31 remained low (Fig5A, B), although there was 
strong elevation in SMA expression (Fig5A, B), indicating differentiation of stroma had occurred. 
Exosome treatment generated extensive and particularly thick vessel-like structures (Fig5A, C), and 
this effect was partly attenuated by SB431542, leading to long but narrow structures (Fig5A, C). 
Diseased stroma was constitutively able to generate extensive, thick vessel-like structures like those 
achieved by exosome-stimulated normal stroma (Fig5A).  
To ascertain the importance of stromal-derived factors in supporting vessel formation, we added a 
range of inhibitors to the system after 72h stimulation of stroma, together with HUVEC, and 
monitored vessel formation as above. Inhibitors included blocking antibody against VEGF-A (31) or 
FGF2 (32), together with isotype-matched control antibody. To inhibit uPA, we added recombinant 
PAI (its natural inhibitor; (33)), and to inhibit the effects of HGF we used a small molecular inhibitor 
of its receptor-cMet (34). Vessel length and width was quantified, revealing the pattern and 
magnitude of the inhibitory effects were comparable between exosome-activated normal stroma and 
untreated diseased stroma (Fig5D). This highlights a requirement for these myofibroblast-derived 
factors in this assay, and further underlines the similarities between exosome-activated normal 
stroma, and constitutive diseased stroma in the angiogenic influence they impart.  
We next explored the ability of differentially generated primary stromal cells to promote tumour 
growth in vivo, using a xenotransplantation model system with immune deficient mice. Du145 
tumour cells were administered subcutaneously, alone or together with different types of primary 
stromal cells, and tumour growth was measured for up to 43 days. Co-administration with normal 
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prostate stroma slightly accelerated tumour growth, with a mean tumour volume 1.9-fold higher at 
day 43 (p<0.05) (Fig5E). With diseased stromal cells, however, there was clear promotion of growth, 
with a volume that was 3.3 times larger (p<0.001). Even though we expected tumour cells to activate 
co-injected stromal cells in situ, we found that pre-treating the normal stroma for only 3-days with 
exosomes prior to grafting gave a sufficient “head-start”, and enhanced tumour growth 2.4 fold 
(p<0.001).  However, 3 day pre-activation using sTGF in a similar fashion drastically reversed 
this stromal influence, resulting instead in tumour retardation. These in vivo findings support our in 
vitro-observations and emphasise the profound differences between exosomally-generated and 
sTGF-generated myofibroblasts.  
 
Cancer exosomes are required to activate tumor-promoting stroma in vivo.  
Inhibition of exosome secretion is an attractive approach to assess their influence in vivo. 
Targeting Rab27a; a regulator of exosome secretion, can generate cells selectively deficient in 
exosome secretion (35). We generated stable transfections of Du145 cells bearing empty vector alone 
(pEF6) or with an anti-Rab27a ribozyme transgene. Successful and selective Rab27a knockdown 
(Rab27a
KD
) was confirmed by western blotting and qPCR (Fig6A). Confocal microscopy showed 
early endosomes, stained with anti-EEA1 antibody, were not affected, but late endosomes/lysosomes 
accumulated LAMP-2 in Rab27a
KD
 cells (Fig6B). Flow cytometric analysis (Fig6C), also showed 
intracellular accumulation of LAMP-2 and CD9, but not EEA-1 following Rab27a
KD
 (Fig6B, C). 
These data are consistent with having targeted late, and not early endosomal compartments and are 
similar to the findings previously reported (35). Importantly for subsequent in vivo studies, the cells 
remained comparably viable, with identical proliferation rates in vitro (Fig6D).  
Secretion of soluble factors by Du145 cells, showed comparable levels of uPA or VEGF-A 
(Fig6E), but decreased TGF of around 20% in the Rab27aKD cells. TGF transcription however 
was unaltered, indicating this was not an off target effect of Rab27a knockdown (Fig6F). Depletion 
of exosomes from the media, by ultracentrifugation, revealed a comparable TGF loss of around 
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15-20% (Fig6G). The impact of Rab27a
KD
 on total secreted TGF is likely due, therefore, to 
reduced exosomal-TGF. The exosome-containing 100,000g pellets generated from control or 
Rab27a
KD
 culture medium showed 70-95% reduction in the exosome-associated proteins TSG101, 
ALIX and Lamp2 (Fig6H). Furthermore, an in-house ELISA was used to measure material within the 
100,000g pellets. This was based on immobilised anti-CD9, to capture exosomes, and anti-MHC 
Class-I-biotinylated antibody as a means of demonstrating CD9/Class-I co-localisation in microplate 
wells. A standard curve, of sucrose-cushion purified Du145 exosomes was used as a means of 
quantitation.  The assay revealed an 82% decrease in exosomes secreted by Rab27a
KD
 cells (Fig6I). 
Together, the data support successful Rab27a knockdown in Du145, with a concomitant selective 
impairment of exosome secretion. 
In functional terms, culture medium from control Du145 cells drove stromal differentiation to an 
SMA-positive myofibroblast phenotype, that supported formation of HUVEC vessel structures in 
vitro (Fig7A, B). Medium from Rab27a
KD
 cells failed to trigger differentiation and subsequently we 
saw a lack of angiogenic effect. Fibroblasts secreted significantly lower levels of uPA, VEGF-A, 
HGF and FGF2 when treated with Rab27a
KD
 culture medium (Fig7C). Because the full impact of 
Rab27a
KD 
on the cancer cell secretome remains incompletely explored, it was possible that the effects 
seen here are due to inadvertent loss of secreted factors by these tumour cells, rather than due to 
exosome-deficiencies. To address this, similar experiments were performed comparing Du145 CM 
with that of CM-following exosome depletion by ultracentrifugation. Such depletion abrogated the 
ability of Du145 CM to drive stromal differentiation and vessel formation. Whilst in contrast, 
reconstituting the exosome pellet in the original volume of fresh medium is sufficient to fully restore 
this functional property. Again, the data point to exosomes, and not soluble factors within the cancer 
cell secretome as the key driver of pro-angiogenic differentiation of stroma (Supplemental FigS2). 
We next investigated the function of exosome-deficient tumour cells in vivo. Control or Rab27a
KD
 
Du145 cells were administered to immune deficient mice alone or together with normal stromal 
fibroblasts, and tumour growth monitored for 32 days thereafter. Control DU145 cells showed 
accelerated growth in the presence of normal fibroblasts (Fig7D). In marked contrast, Rab27a
KD
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Du145 cells showed no growth enhancement whatsoever in the presence of fibroblasts. This lack of 
stimulated growth upon stromal co-administration was highly significant (p<0.001) in this 
experiment, and the findings are consistent with failure of Rab27a
KD
 Du145 cells to achieve 
activation of stroma in situ.  
 
Discussion 
We show a critical role for TGF bearing cancer exosomes in generating tumour-promoting 
stroma. Exosomes achieve these effects through driving fibroblast differentiation to a myofibroblast-
like phenotype that supports angiogenesis in vitro, and tumour growth in vivo. These exosome effects 
are TGF-dependent, yet generate a myofibroblast that is absolutely distinct from that generated 
using sTGF. The study emphasises that the biophysical format of this particular growth factor is 
crucial in directing the cellular response and subsequent pathological changes that arise. 
TGF is documented as the central factor implicated in altering stroma at diverse sites of 
carcinoma (2). Our report doesn’t dispute such findings, as TGF drives the principal effects we 
demonstrate with exosomes, however, stromal-myofibroblasts generated by sTGF or exosomal-
TGF are clearly different. Whilst cytoskeletal changes do not well discriminate this, the analysis of 
secreted factors reveal major differences in levels of multiple angiogenic factors, including uPA, 
HGF, VEGF-A and FGF2. Using primary prostate stromal cells, the ability of exosomes alone to 
drive normal stroma to a pro-angiogenic disease-like phenotype is of particular interest; and is not 
possible using sTGF. Whilst forming only ~20% of the total TGF present in the tumour cell 
secretome exosomal, not soluble, TGF dictates the nature of stromal differentiation that occurs.  
Rab27a knockdown, or ultracentrifugation-based depletion of exosomes, renders tumour cell 
conditioned media unable to trigger fibroblast differentiation. Such effects are recapitulated in vivo, 
where defective exosome secretion render tumour cells impervious to the otherwise positive growth 
promoting influence of stroma. A degree of caution is required here, however, as currently we do not 
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know if other factors are inadvertently abrogated by the Rab27a targeting approach in these cells. 
Nevertheless, adding purified exosomes, or removing exosomes by physical means or by modulating 
their secretion, gives a consistent effect with respect to stromal alterations in vitro, and to date the 
Rab27a targeting approach is among the most appropriate tools available to aid the study of exosome 
effects in vivo.  
A key distinguishing feature of soluble vs exosomal-TGF1 delivery is the role of the TGF-RIII 
(Betaglycan), and possibly other membrane-associated proteoglycans. Betaglycan is known to tether 
TGF to the exosome outer surface (12), and hence exosomes deliver Betaglycan-associated 
TGFto recipient stromal cells.  As well as acting as a ligand-sink for TGF,  Betaglycan plays 
established functions in co-reception, controlling hand-over of TGFto the type-I and II receptors 
thereby facilitating signalling (36). We show that digestion of HS-side chains from exosomes, whilst 
having no impact on the delivered TGF dose, severely attenuates exosome induced SMAD3-
dependent TGF1 signalling, resulting in failed stromal differentiation and subsequent loss of 
angiogenic response. Therefore, delivery of TGF in the context of intact HS-side chains is essential 
for the effects we observe, and is a critical aspect that distinguishes soluble from vesicular delivery of 
TGF. 
In conclusion, we show the essential role of extracellular vesicles in communication between 
cancer cells and surrounding stroma and demonstrate that exosomal-TGF is required for directing 
stromal differentiation to a pro-tumourigenic phenotype. Pathways therefore related to exosome-
biogenesis/secretion, or molecules like HSPGs directing TGF-delivery or other physical interactions 
between exosomes and stromal cells, are highlighted as targets for future therapeutic approaches 
aimed at abrogating this critical process in tumour progression.  
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Materials and Methods 
Cell culture.  
Prostatic stromal cells, from four patients, were obtained from the Wales Cancer Bank. Cells were 
isolated from radical prostatectomy cores by homogenization and 15h collagenase I digestion 
(200U/ml, Lonza). Cells were cultured in Stromal Cell Basal Medium (Lonza) then, following first 
harvest, DMEM/F12 media (Lonza). Cultures were confirmed free of epithelial cells by immuno-
fluorescence staining for Cytokeratin, and used at passage 2-4.  Normal lung fibroblasts (Coriell 
Institute for Medical Research) were maintained in DMEM/F12. Primary HUVEC (Lonza), were 
cultured in Endothelial Growth Media (EGM)-2 (Lonza).  
 
Exosome Isolation.  
Du145 prostate cancer cells (ATCC, Teddington, UK), were grown in Integra bioreactor flasks 
(37). Exosomes were purified from cell conditioned media, based on their flotation properties (38), 
using the sucrose cushion method (39). Exosomes were resuspended in PBS, quantified using the 
BCA-protein assay (Pierce/Thermo), and stored at -80
o
C. Typical exosome characterisation (12, 39) 
is shown in FigS1. Unless stated otherwise, exosomes were used at 200 g/ml which gives a TGF 
dose equivalent to 1.5 ng/ml (12). 
 
Protein array & ELISA.  
Stimulated cells were incubated with Golgi-Stop
TM
 and Golgi-Plug
TM
 (Becton Dickinson) 18h 
prior to lysis, to prevent cytokine secretion. Samples were corrected for protein differences and 
analysed using an angiogenesis protein array kit (R&D Systems). Quantitation of secreted proteins 
was performed using the DuoSet ELISA Development System; (R&D Systems). An exosome ELISA 
was developed in-house, using anti-CD9 antibody (R&D systems) coated ELISA strips (Greiner), 
BSA to block (R&D Systems), detected with anti-MHC Class-I biotin conjugate (Leinco 
Technologies) and streptavidin-Europium (PerkinElmer), using the Delphia assay and wash buffer 
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system (Perkin Elmer). ELISA strips were read on a Wallac Victor
2
 1420 (PerkinElmer) and counts 
compared to sucrose-cushion purified Du145 exosomes as standards. 
 
Quantitative RT-PCR.  
Extraction of cellular RNA and quantitative RT-PCR was performed as previously described (12).  
 
Immuno-fluorescent microscopy and time-resolved fluorimetry.  
Following treatment, cells were fixed with ice cold acetone:methanol (1:1) for 5 min, dried and 
blocked in 1%BSA/PBS for 1h, then stained with primary antibodies (1g/ml, Santa Cruz) for 1h. 
For time-resolved fluorimetry, detection was achieved using an anti-IgG-biotin conjugate (GE 
Healthcare), and europium-conjugated streptavidin (PerkinElmer) as described previously (12).  This 
approach was used to examine heparinase-III digestion of exosomes, staining post-digest with anti-
HS (F69-3G10, Seikagaku Biobusiness Corporation) (30). For epifluorescence or confocal 
microscopy, primary antibodies were detected using goat anti-mouse IgG Fab’ Alexa488 conjugated 
(Invitrogen) and nuclei stained with DAPI. Confocal images were acquired on a Leica SP5 confocal 
laser scanning microscope (Milton Keynes, UK) equipped with Argon (Alexa488) and Blue Diode 
(Hoechst33342) lasers, a 63x/1.4 numerical aperture oil-immersion objective and Leica LAS AF 
software. Shown are representative figures from z-axis sections overlaid to generate maximum 
projection images.  
 
Analysis of cell proliferation and viability.  
Endothelial cell proliferation was assessed by thymidine incorporation assay as described (40), 
and viability quantified using Guava ViaCount
TM
 flow cytometric system (Millipore). Manual counts 
with Trypan blue exclusion was performed in quadruplicate for Rab27a
KD
 DU145 cells. 
 
Endothelial vessel-formation assay.  
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A method similar to Sheldon et al (24)  was used to assess formation of endothelial vessel-like 
structures, on fibroblast monolayers pre-treated as specified. Endothelial cells, starved of growth 
factors for 24h, were added to fibroblasts (5:1 fibroblasts:endothelial cells), in a 1:1 volume of 
DMEM/F12:EGM2, in the absence of exogenous factors. Co-cultures were maintained for 5-7 days 
then immuno-fluorescently stained for CD31. ImageJ software (National Institutes of Health, USA), 
was used to quantify vessel length and width (≥4 fields of view), for each of three replicate wells. 
Data shown is representative of 3 independent experiments using lung fibroblasts. Prostate stroma 
experiments were conducted using matched cells from 4 patients (each repeated at least twice). Data 
shown are representative of donor-1, used for in vivo experiments. Where stated, growth factors were 
inhibited using VEGF or FGF neutralizing antibody (2g/ml, R&D Systems), uPA inhibitor rhPAI-1 
(2g/ml, Sigma), and MET kinase inhibitor (2g/ml, Calbiochem) to attenuate HGF receptor-cMet 
activation (31-34). Inhibitor concentrations were determined based on the manufacturers 
neutralization dose (ND50). 
 
Xenotransplanted tumour growth.  
Suspensions (100µl) containing 300,000 Du145 cells and 75,000 primary stromal cells, in 3mg/ml 
Matrigel were sub-cutaneously injected into the flanks of 4 – 6 week old athymic nude mice (CD-1; 
Charles River Laboratories, UK). Tumour size, 4 mice per group, was measured weekly. Animals 
were treated humanely in accordance with UK Home Office and the United Kingdom Coordinating 
Committee on Cancer Research (UKCCCR) guidelines. At the experimental end point, or severity 
limits, animals were dispatched humanely by schedule 1. Tumour volume was calculated; tumor 
volume = 0.523 x width
2
 x length. For Rab27a
KD
 details are identical, except we administered twice 
the cell numbers, with 2 tumours per mouse (opposite flanks).   
 
Rab27a knockdown.  
Ribozyme transgenes specifically targeting human Rab27a were designed using Zuker’s RNA 
mFold programme (41) and synthesized by Sigma (Sense 5’–
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CTGCAGCACTAGTTTCAAAGTAGGGCTGATGAGTCCGTGAGGA–3’; Antisense 5’–
ACTAGTGAAAGAGGAG-GAAGCCATAGCACTCGCAGAGAAATATGGAATTTCGTCCT-
CACGGAC–3’). Ribozyme transgenes were cloned into mammalian pEF6/V5-His TOPO plasmids 
(Invitrogen), amplified in chemically competent E. coli, and plasmid uptake confirmed by resistance 
to ampicillin (100g/ml). Correct transgene orientation was confirmed by PCR, prior to overnight 
colony expansion. Purified plasmid DNA (2.5g) was transfected into 1x106 Du145 cells by 
electroporation (Flowgene, UK). Plasmid-positive cells were selected based on blastocydin (Sigma) 
resistance (42). 
 
Electrophoresis and immuno-blotting.  
Rab27a knockdown was confirmed by immuno-blotting whole cell lysates with anti-Rab27a 
(Santa Cruz) or anti-GAPDH (BioChain, Abingdon, UK) antibodies. The impact on exosome 
secretion was examined by immuno-blotting of pellets obtained after 100,000g ultracentrifugation, 
staining for TSG101, ALIX and LAMP-2 (Santa Cruz). Blotting was performed as previously 
described (12). For HSPG analysis, immuno-blotting was performed on exosomes (20g/lane) 
following heparinase-III digestion, and HS-stubs detected using 1g/ml of anti-HS antibody (F69-
3G10; Seikagaku Biobusiness Corporation) (30).  
 
TGF reporter assay. 
TGF signalling was assessed by transfecting fibroblasts with the SMAD3-responsive promoter 
construct (SBE)4-Lux, as previously described (43). After 24h, cells were washed with PBS, and 
treated with serum-free medium containing exosomes or rhTGF-1 for 6h. Luciferase activity was 
measured using the Dual-Glo luciferase activity kit (Promega).  
 
Flow cytometric analysis.  
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Du145 cells were fixed/permeabilised, stained with monoclonal antibodies against EEA1 (Becton 
Dickinson), LAMP2 (Santa Cruz), or CD9 (R&D Systems), and analyzed on a FACSCanto 
cytometer running FACSDiva V6.1.2 software (Becton Dickinson).  
 
Statistical analysis.  
Statistic analyses were performed using Prism-4 software V4.03 (Graph Pad, San Diego, CA). In 
experiments with more than two experimental groups 1-way ANOVA with Tukey’s post-test was 
used, except for migration and in vivo experiments where a 2-way ANOVA with Bonferroni post-test 
was used. Experiments with two experimental groups were evaluated using students t test. P values 
less than 0.05 are considered significant *p<0.05, **p<0.01, ***p<0.001. Graphs depict mean±SE, 
from one representative experiment of at least three similar experiments, unless stated otherwise. 
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Figure Legends 
 
Figure1. Cancer exosomes generate a distinctive myofibroblast phenotype.(A) Growth arrested 
(72h) lung fibroblasts were stimulated for 72h with exosomes (exo), exosomes with the ALK5 
inhibitor SB431542 (exo SB) or as indicated, and expression of SMA or other markers were 
measured by time resolved fluorimetry (TRF) (mean+SE, n=4). (B) Scanned image of an 
angiogenesis protein array performed on fibroblast cell lysates normalized for protein, following 72h 
stimulation with sTGF (at 1.5ng/ml) or matched dose of exosomal-TGF(C) Densitometry-based 
comparison of these treatments depicting proteins differentially expressed by exosomes vs TGF 
treatment, representative of 3 such experiments. (D) ELISA of fibroblast conditioned media collected 
72h post stimulation with sTGF (white bars at 0, 0.375, 0.75, 1.5, 3 ng/ml) or matched doses of 
exosomal-TGF (black bars) (mean+SE, n=3). (E) Quantitative PCR analysis of fibroblast mRNA at 
72h following treatment with exosomes with or without SB431542 or as indicated, showing relative 
expression compared to untreated fibroblasts (mean+SE, n=3). (F) As for (B) and (C), an 
angiogenesis protein array was performed, comparing fibroblasts stimulated with exosomes in the 
presence or absence of SB431542, revealing the TGF sensitive nature of exosome-driven changes.  
 
Figure2. Exosome-generated myofibroblasts are pro-angiogenic. (A) Conditioned media from 
fibroblasts stimulated for 72h with exosomes or as indicated, were added to HUVEC monolayers for 
24h, and expression of CD31 and other factors measured by time resolved fluorimetry (TRF) 
(Mean+SE, n=3). (B) HUVEC treated as indicated were pulsed with 3H-Thymidine for the last 18h of 
a 72h incubation, and as a measure of proliferation, 3H-Thymidine uptake was measured (mean+SE, 
n=4). (C) HUVEC viability was assessed at 72h using Guava ViaCount (Mean+SE, n=3). (D) A 
HUVEC monolayer scratch assay was performed in the presence of conditioned media from 
fibroblasts previously treated with exosomes or as indicated. The scratch width was measured at 
multiple points along the scratch (examples in black line (D), scale bar= 100m). Line graph depicts 
measurements over a 24h period. (E) Fibroblasts were stimulated with exosomes or as indicated for 
72h, and HUVEC were added. After 6d of co-culture, cells were fixed, and examined for CD31 
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positive structures by immuno-fluorescence. Typical images show differences in vessel-like 
structures across the treatments (scale bar=100m). Bar graphs depict the vessel width and vessel 
length, from 4 fields of view for each of 3 replicates (Mean±SE). Representative of three such 
experiments. 
 
Figure3. Cancer exosomes require GAG chains for TGF delivery to fibroblasts. (A) Du145 
exosomes were untreated (No enzyme), treated with active heparinase-III for 1h, or with heat 
inactivated heparinise-III. Treated exosomes (20 g/lane) were examined by SDS-PAGE/Western 
blot, staining with the anti-HS antibody, or anti-TSG101 or anti-GAPDH as indicated. (B) Similarly 
treated exosomes were subjected to 2x ultracentrifugation washes, to remove solubilised material, 
and analysed using a TGF1 ELISA (Mean±SE, n=3). (C) Similarly prepared exosomes were added 
to lung fibroblasts for 6h and SMAD3-dependent TGF signalling was compared to that of untreated 
fibroblasts, measured by luciferase-based reporter assay (Mean±SE, n=4). (D) Fibroblasts treated 
with washed, heparinase-III digested exosomes, or as specified, were stained at day-3 for SMA 
expression (left), or HUVEC added for a further 7 days, and stained for CD31-positive structures 
(right). Typical images show differences in myofibroblast differentiation and vessel-like structures 
across the treatments (scale bar=100m). (E) Bar graphs depict the average vessel width and length, 
from 4 fields of view for each of 3 replicates. Representative of three such experiments. In (D) and 
(E), an additional control where active enzyme was subject to ultracentrifugation washes (x2) prior to 
adding any pelleted material to exosomes, and then to fibroblasts, to account for potential trace 
enzyme in the system impacting fibroblasts directly. (F) Cell media collected from similarly treated 
fibroblasts at 72h, were analysed by ELISA for levels of HGF (left) and VEGF-A (right) (Mean±SE, 
n=3). 
 
Figure4. Cancer exosomes can generate a diseased-like stromal phenotype. (A) Biopsies taken 
from a radical prostatectomy of a prostate cancer patient, from a non-involved and from a diseased 
region of the prostate. H&E stain reveals gross differences in tissue architecture consistent with 
normal (left) or disease with high Gleason score (right). (B) Cultures established from these tissues 
 24 
were analyzed by immuno-fluorescence for the myofibroblast marker SMA, with either no treatment, 
or following exosome or sTGF treatment for 72h (scale bar=100m). (C) Parallel experiments were 
used to examine relative changes in SMA, Vimentin or Desmin expression by time resolved 
fluorimetry (TRF) (mean±SE, n=3). (D) Conditioned media from these primary stromal cells, collected 
at 72h following stimulation as indicated, were examined by ELISA for VEGF-A, uPA, HGF and 
FGF2. (Mean±SE, n=3). The data are representative of isolates from four patients. 
 
Figure5. Normal primary stromal cells become pro-angiogenic following cancer exosome 
treatment.  (A) Primary stromal cells, taken from histologically confirmed normal or cancerous tissue, 
were stimulated at passage 3, with exosomes or as indicated, and at 72h HUVEC cells were added. 
After 6 days co-culture, formation of CD31-positive vessel-like structures was assessed by immuno-
fluorescence microscopy. Parallel wells were setup to examine SMA expression by stromal cells. 
(B) The relative levels of SMA or CD31 expression were measured by time resolved fluorimetry 
(TRF) (Mean±SE, n=3). (C) Measurements of vessel width (left) or vessel length (right) were taken 
from 4 fields of view for each of 3 replicates (mean±SE). (D) In a similar assay, inhibitors against 
VEGF, FGF, uPA (its inhibitor; PAI-I) or HGF (inhibitor of its receptor; cMET) were added together 
with HUVEC to exosome-activated normal stroma or untreated diseased stroma. Graphs depict 
vessel width or length, taken from 4 fields of view for each of 3 replicates (mean±SE). (E) Du145 
tumour cells (3x10
5
) were administered subcutaneously to immune deficient mice in the absence or 
presence of human prostatic stromal cells (7.5x10
4
), and tumour volume was measured at intervals 
up to 43 days (mean±SE, n=4/group). Normal stromal cells were either untreated, or pre-treated for 
72h with exosomes or sTGF1, prior to administering. As a comparator, untreated diseased stroma 
(from the same patient) was used. Stroma in the absence of tumour cells did not grow a measurable 
volume (not shown). 
 
Figure6. Inhibition of Du145 cell exosome secretion, by targeting Rab27a. (A) Cell lysates of 
control or Rab27a
KD
 cells were examined by western blot, staining for Rab27a or GAPDH as 
indicated. Densitometric analysis of blots from three independent experiments (mean±SE, n=3), 
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confirms successful Rab27a protein knockdown. Confirmation of selective decrease in Rab27a-
mRNA (line graph) assessed by qPCR. (B) Confocal images of control or Rab27a
KD
 cells, with 
immuno-fluorescent staining for the early endosomal marker EEA-1 or for LAMP-2 (scale bar= 25m) 
(C) Flow cytometric analysis of fixed vs fix/permeabilised cells stained for EEA1, LAMP-2 or CD9, 
comparing control and Rab27a
KD
 cells (MFI=median fluorescence intensity, based on 30,000 events). 
(D) Cell and viability counts, by trypan blue exclusion performed serially for 2 weeks comparing 
parallel cultures of control or Rab27a
KD
 cells (mean±SE, n=4). (E) Cell conditioned media from 
control and Rab27a
KD
 cells (corrected for cell number), was analyzed by ELISA for secreted uPA, 
VEGF-A and TGF1, with data normalized for control cells set to 100% (mean±SE, n=4). (F) Q-PCR 
for TGF mRNA isolated from control and Rab27a
KD
 cells, showing relative expression normalized to 
control cells (mean±SE, n=4). (G) Du145 culture media was spun at 100,000g/1h, and the media pre- 
and post- centrifugation analyzed for TGF1 by ELISA, with data normalized for control cells set to 
100% (mean±SE, n=4). (H) Western blots, of material which pellets at 100,000g, from control or 
Rab27a
KD
 cells, normalized for cell number, staining for TSG101, ALIX and LAMP2, representative of 
3 such experiments (bar graphs shows densitometric analysis, mean±SE, n=3) (I) Resuspended 
100,000g pellets, obtained from control or Rab27a
KD
 cells, corrected for cell number, were analyzed 
by an in house exosome-ELISA based on capturing with anti-CD9 antibodies and detecting using 
anti-MHC Class-I antibodies, (mean±SE, n=4). 
 
Figure7. Exosome secretion is required for recruitment of pro-angiogenic and tumor 
promoting stroma. (A) Conditioned media (CM) from control or Rab27a
KD
 cells were added to 
growth arrested normal stromal cells, and after 72h cells were either fixed and stained for SMA, or 
HUVEC added for a further 5 days, followed by fixation and staining for CD31. Untreated stromal 
cells were included as a negative control (scale bar= 100m). (B) Measurements of vessel width or 
vessel length were taken from 4 fields of view for each of 3 replicates (mean±SE). (C) Soluble factors 
were measured in stromal-cell conditioned media by ELISA, following 72h treatment with CM from 
control or Rab27a
KD
 cells (mean+SE, n=3). (D) Control or Rab27a
KD
 DU145 cells (6x10
5
) were added 
in the absence or presence (+Fb) of normal stromal cells (1.5x10
5
), subcutaneously to immune 
deficient mice, and tumour volume measured at intervals up to 32 days (mean±SE, n=8/group).  
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Legend for Supplemental Fig s1. Exosome Characterisation. (A). A continuous sucrose gradient 
was used to determine the density of vesicles secreted by the Du145 prostate cancer cell line. The 
refractive index of collected fractions was measured, and the density calculated as described (39). 
After washing by ultracentrifugation, fractions were immobilised to protein-binding ELISA-plates, and 
stained with anti CD9, CD63 or isotype control antibodies, using an indirect staining protocol, with a 
biotinylated secondary antibody. Signal intensity was determined by measuring the binding of 
streptavidin-Europium conjugate, by time resolved fluorimetry (TRF). (B) Based on this flotation 
characteristic, exosome were isolated by a simplified sucrose cushion-approach throughout the 
study, and such purifications exhibited characteristic enrichment of certain exosomal-makers 
compared to cell lysates, demonstrated by western blot (10 g protein / lane) and as a measure of 
purity, Calnexin is shown poorly detected in exosomes. (C) Size distribution histogram of sucrose 
cushion purified exosomes, measured by Nano-particle tracking analysis, revealing a population of 
small particles with a mode of 115nm. Shown are the mean of 6 replicates (grey line) with +SE-
depicted by the dotted black lines (C, inset) presence of vesicular structures by TEM (D). Sucrose 
cushion purified exosomes, immobilised to protein-binding ELISA plates (at a dose of 1, 0.2 or 0 
g/well), and stained for classical exosomal-surface markers as indicated using the same method as 
described for (A) above. Bars show mean+SE of duplicates. 
 
Legend for Supplemental Fig s2. Exosome secretion is required for differentiation of pro-
angiogenic stroma. (A) The concentration of nano-particles was determined by nano-particle tracking 
analysis, on conditioned media (CM) from Du145 cells, before (Control) and following 
ultracentrifugation at 100,000g 1h (Exo-depleted CM). The exosome-containing pellet was 
resuspended in the original volume, and analysed again (Exo-pellet Reconstituted) (Mean±SE, n=6). 
(B) Stromal cells were left untreated or treated with Du145 CM, exosome-depleted CM or 
reconstituted pellet (in the original volume of fresh medium). At 72h stromal differentiation was 
assessed examining expression of SMA.  HUVEC were then added to parallel wells, for an 
additional 5 days, at which point formation of vessels was examined by staining for CD31 (scale bar= 
100 µm). 
